What does this TikTok actually claim?
Cate Elam posted a visual guide showing how to self-inject tirzepatide, a GLP-1 receptor agonist she gets through Ivim Health. The video demonstrates injection technique and promotes a telehealth platform for GLP-1 access.
She's promoting both the medication and the specific telehealth service through affiliate marketing. The video focuses on the practical "how-to" aspect rather than making specific medical claims about effectiveness or safety.
Is her injection technique actually correct?
The basic injection steps she shows align with standard subcutaneous injection protocols used in clinical trials. Tirzepatide is administered as a weekly subcutaneous injection, typically in the abdomen, thigh, or upper arm.
However, without seeing her exact technique details, it's impossible to verify if she's demonstrating proper site rotation, needle angle, or injection speed. The SURPASS trials that established tirzepatide's efficacy used standardized injection protocols that patients received proper training on.
Self-injection education should come from healthcare providers, not social media. The FDA-approved prescribing information includes specific injection instructions that differ between pen devices and vials.
What's the deal with Ivim Health and telehealth GLP-1s?
Telehealth platforms like Ivim Health have exploded as demand for GLP-1 medications outpaces supply. Many operate legally by connecting patients with licensed physicians who can prescribe these medications off-label for weight management.
The problem? Quality control varies wildly between platforms. Some use compounding pharmacies to create custom formulations when brand-name drugs aren't available. These compounded versions aren't FDA-approved and lack the rigorous testing of medications used in trials like SURMOUNT-1.
Cate's affiliate relationship creates a financial incentive that viewers should know about. She benefits when people sign up through her link, which could influence how she presents the information.
Does tirzepatide actually work for weight loss?
Yes, and the data is impressive. The SURMOUNT-1 trial (Jastreboff et al., NEJM, 2022) found that tirzepatide led to weight reductions of 16.0%, 21.4%, and 22.5% at 5mg, 10mg, and 15mg doses respectively over 72 weeks.
That's significantly better than semaglutide's 14.9% weight loss in the STEP 1 trial. Tirzepatide targets both GLP-1 and GIP receptors, which may explain its superior effectiveness.
But here's what Cate doesn't mention: 31% of participants in SURMOUNT-1 experienced nausea, and 25% had diarrhea. The STEP 1 trial showed similar gastrointestinal side effect rates. These aren't minor inconveniences for many people.
What should you actually know about GLP-1s?
The clinical trial results are compelling, but real-world use often differs from controlled studies. The STEP 1 extension study showed that people regained about two-thirds of their lost weight after stopping semaglutide.
Cost matters too. Brand-name tirzepatide (Mounjaro, Zepbound) can cost over $1,000 monthly without insurance coverage. Telehealth platforms often promote compounded versions at lower prices, but these lack long-term safety data.
Getting these medications through established healthcare providers ensures proper monitoring for side effects like pancreatitis, which occurred in 0.2% of tirzepatide users in clinical trials. TikTok tutorials can't replace medical supervision.